OACC

Oaktree Acquisition Corp. III Life Sciences
CAPPED RATING

Oaktree Acquisition Corp. III Life Sciences (OACC) is rated C- (1.9/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Momentum (B-); its weakest is Value (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
D-
Factor Score 0.8 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 38.2
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -0.9%
Price Return 12M 0.9%
Catalyst Signal 0.00
Market Cap $141.8M
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 D- (0.8) D+ (1.6) D (1.5) B- (2.9) C+ (2.5) C- (1.9)
2026-11-06 D- (0.7) D+ (1.6) D (1.5) C+ (2.8) C+ (2.5) D+ (1.8)
2026-10-30 D- (0.8) D+ (1.6) D (1.5) C+ (2.8) C+ (2.5) D+ (1.8)
2026-10-23 D- (0.8) D+ (1.5) D (1.5) C+ (2.6) C+ (2.5) D+ (1.8)
2026-10-16 D- (0.8) D+ (1.5) D (1.5) C+ (2.5) C+ (2.5) D+ (1.8)
Page 1 of 4